Previous 10 | Next 10 |
– Advisory committee voted 8-6 in support of accelerated approval of SRP-9001 – Regulatory action date is May 29, 2023 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Foo...
2023-05-12 18:31:20 ET A panel of advisors to the US FDA has voted that the benefits of Sarepta Therapeutics' ( NASDAQ: SRPT ) gene therapy SRP-9001 for Duchenne muscular dystrophy outweigh the risks. The vote from members of the Cellular, Tissue, and Gene Therapies Advis...
2023-05-12 15:03:55 ET Shares of contract manufacturer Catalent ( NYSE: CTLT ) continued to tumble on Friday to reach a new 52-week low, while Jefferies reaffirmed its Buy rating despite the company’s recent decisions to lower guidance and delay Q3 financials. Catalent ( ...
2023-05-12 08:27:11 ET Sarepta Therapeutics ( NASDAQ: SRPT ) shares are on hold for trading as a group of independent experts at the FDA is scheduled to meet on Friday to weigh in on its marketing application for gene therapy SRP-9001 targeted at Duchenne muscular dystrophy. The...
2023-05-12 00:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-11 14:23:41 ET Shares of the rare disease juggernaut Sarepta Therapeutics (NASDAQ: SRPT) fell by 12.6% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The biotech's stock fell almost on cue ...
2023-05-10 08:39:21 ET Sarepta Therapeutics ( NASDAQ: SRPT ) fell ~2% pre-market Wednesday after the FDA posted briefing documents ahead of an advisory committee meeting on May 12, 2023, regarding the company's marketing application for gene therapy SRP-9001. In April, Sarep...
2023-05-03 00:00:25 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q1 2023 Earnings Call May 02, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q1 2023 Earnings Ca...
2023-05-02 20:52:02 ET Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Conference Call May 02, 2023 4:30 PM ET Company Participants Mary Jenkins – Associate Director-Investor Relations Doug Ingram – President and Chief Executive Officer Louise Ro...
2023-05-02 16:10:04 ET Sarepta Therapeutics press release ( NASDAQ: SRPT ): Q1 GAAP EPS of -$5.86 misses by $4.57 . Revenue of $253.5M (+20.3% Y/Y) beats by $12.03M . For further details see: Sarepta Therapeutics GAAP EPS of -$5.86 misses by $4.57, revenu...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...